Spectrum of use and tolerability of 5‐HT3 receptor antagonists

Abstract

Several 5‐HT3 receptor antagonists are available (tropisetron, ondansetron, granisetron, dolasetron, and palonsetron), and further compounds are in clinical development. These substances show only minor differences in the activity profile regarding their affinity for particular receptors.5‐HT3 receptor antagonists are primarily used and found effective in the prevention and treatment of chemotherapy‐induced nausea and emesis, and in postoperative nausea and vomiting (PONV). Antagonism of the 5‐HT3 receptors in the peripheral and central nervous system is a probable mechanism of action.The substances are suitable as first‐line therapy (combined with a corticosteroid) for the prevention of acute nausea and vomiting in patients treated with moderately to severely emetogenic chemotherapeutic agents. This combination is also moderately effective in the prevention of delayed nausea and vomiting. 5‐HT3 receptor antagonists are an important constituent in the prevention and treatment of emesis and nausea caused by radiation therapy, especially in patients receiving whole body or upper abdominal treatment.Alosetron was found clinically effective in diarrhoea‐predominant irritable bowel syndrome, whereas tropisetron in fibromyalgia and related pain disorders. Further indications for such treatment include anxiety disorders, alcohol dependence, drug withdrawal, and psychosis related to treatment of Parkinson's disease.5‐HT3 receptor antagonists are well tolerated with the most frequently reported adverse effects being headache, constipation, dizziness, tiredness, and gastrointestinal disturbances such as abdominal pain or constipation. Intravenous administration of serotonin induces the Bezold‐Jarisch reflex and causes small reversible changes in electrocardiogram (ECG) parameters.